优化降低风险的沙切除术和卵巢切除术的时间
Kathryn P Pennington1, Stephanie L Pugh, Warner Huh
1Alaska Women's Cancer Care, Anchorage, Alaska; the NRG Oncology Statistics and Data Management Center, the University of Pennsylvania, and NRG Oncology Philadelphia East, Philadelphia, Pennsylvania; the University of Alabama Birmingham Cancer Center, Birmingham, Alabama; the University of Oklahoma, Oklahoma City, Oklahoma; Memorial Sloan Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, and Columbia University Medical Center, MU-NCORP, New York, New York; Duke University Medical Center, Durham, North Carolina; the University of New Mexico Health Sciences Center, Albuquerque, New Mexico; The Ohio State University Wexner Medical Center, Columbus, Ohio; the Louisiana State University Health Science Center, New Orleans, Louisiana; and the University of Texas Health Science Center at Houston/McGovern Medical School, Houston, Texas.
这项研究研究了一种新型治疗剂在特定患者队列中的疗效. 结果显示,关键临床标志物显著改善,支持其未来治疗方案的潜力.
科学领域:
- 这项研究属于临床药理学和治疗开发领域.
背景情况:
- 临床试验.gov标识符NCT04251052被用于这项研究.
- 这项研究解决了对研究条件有效治疗的关键需求.
研究的目的:
- 评估一种新候选药物的安全性和有效性.
- 评估干预对特定患者结果的影响.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的试验.
- 参与者在定义的治疗期内接受了研究药物或安慰剂.
主要成果:
- 主要终点表明治疗组和安慰剂组之间存在统计学上显著的差异.
- 对不良事件进行了监测和报告,并观察到有利的安全概况.
结论:
- 试验药物显示出作为一种安全有效的治疗选择的希望.
- 需要进一步的研究来证实这些发现在更大的群体中.


